[Translation] A randomized, double-blind, double-dummy, multicenter phase II clinical trial to evaluate the efficacy and safety of Yinqu Capsule in the treatment of dyslipidemia using Xuezhikang Capsule as a control

初步评价银曲胶囊治疗血脂异常（脾气虚弱，痰瘀阻滞证）有效性和安全性,为Ⅲ期临床试验提供用药依据。

[Translation]

To preliminarily evaluate the effectiveness and safety of Yinqu Capsule in the treatment of dyslipidemia (weak spleen qi and phlegm and blood stasis syndrome) and provide a basis for medication for Phase III clinical trials.

Start Date19 May 2010

Sponsor / Collaborator

Nanjing Hailing Traditional Chinese Medicine Pharmaceutical Art Technical Research Co Lt

[+1]

100 Clinical Results associated with Yinqu Capsule

100 Translational Medicine associated with Yinqu Capsule

100 Patents (Medical) associated with Yinqu Capsule

Literatures (Medical) associated with Yinqu Capsule

01 Dec 2022·Combinatorial Chemistry & High Throughput Screening

Exploring the potential mechanism of Yixiang capsule immune-enhancing function based on Network Pharmacology, Molecular docking, and Animal function experiment

Article

Author: Xiao, Wei ; Wang, Jing ; Bai, Weirong ; Ding, Yan ; Wang, Zhenzhong ; Deng, Chenchen

Background:The Yixiang capsule with traditional Chinese herbs Cistanches Herba, Hedysarum multijugum Maxim,Fructus Ligustri Lucidi,and Fructus lycii are the main raw materials in a modern herbal medicine preparation containing corresponding bioactive ingredients after extraction and processing. This study aimed to investigate the immune-enhancing function of the Yixiang capsule and explore its potential mechanism.Methods:After oral administration of the Yixiang capsule to mice for 30 days, the spleen lymphocyte transformation activity, NK cell activity, DTH, macrophage phagocytosis, HC50 value, amounts of antibody-producing cells, carbon particle clearance rate, spleen, and thymus index were determined to evaluate the regulation effect of the Yixiang capsule on immune function. The potential mechanism underlying the immune-enhancing function of the Yixiang capsule was studied based on network pharmacology and molecular docking.Results:The results showed that the Yixiang capsules can obviously increase the HC50 values in all groups, significantly enhance the DTH reaction of mice, the carbon clearance function in medium and high dose groups,and the phagocytic function of macrophages in high dose groups, but had no significant effect on NK cell activity, T lymphocyte proliferation, body weight and immune organ weight of mice. A total of 78 compounds of the Yixiang capsule may affect 123 metabolic pathways and 1022 GO terms by regulating 232 targets, such as the cancer signaling pathway and the signal pathways of response to lipopolysaccharide, and the key targets predicted could stably bind to the core active components of the Yixiang capsule.Conclusion:These results suggested that the Yixiang capsule could enhance the immune function of mice and have the characteristics of a multi-component and multi-target synergistic effect on the enhanced immunity function, which provides the basis for the follow-up study.

01 Dec 2020·BMC Complementary Medicine and TherapiesQ3 · MEDICINE

Network pharmacology-based study on the mechanism of Yiganling capsule in hepatitis B treatment

Q3 · MEDICINE

ArticleOA

Author: Lu, Chao ; Zhou, Renpeng ; Fu, Wanjin ; Hu, Wei

AbstractBackgroundYiganling (YGL) capsule is a traditional Chinese medicine preparation consisting of eight herbs that has been clinically proven to have a favorable treatment effect on Hepatitis B (HB). However, due to its multiple targets and multi-pharmacological effects, the mechanisms of YGL capsule in the treatment of HB are unknown.MethodsFirst, the chemical constituents of YGL capsules were obtained from the Chinese medicine database, and YGL capsules were constructed. Second, active compounds were screened by the ADME model. The target fishing model was used to screen the corresponding targets of active compounds and to construct a compounds and compound targets network. Using human disease databases and literature mining, we systematically identified genes associated with HB, constructed disease-specific protein-protein interaction networks, and performed clustering and enrichment analyses of these networks. These networks were then merged to obtain a compound-disease target network, and cluster and enrichment analyses were performed on the compound-disease target network to acquire a compounds-disease targets-mechanism network and a clustering network.ResultsWe successfully built eight pharmacological network diagrams, including four primary networks and other network maps. The four dominating network maps included a HB disease-associated protein-protein interaction network, a YGL capsule compounds-target network, a YGL capsule ingredient target-HB disease target network, and a YGL-HB disease mechanism network. Other networks included a pathway of HB disease targets, the HB disease protein-protein interaction cluster analysis network, and the YGL-HB target clustering network.ConclusionThis study successfully forecasted, illuminated, and confirmed the synergistic effects of HB disease molecules and discovered the potential of HB relevant targets, clusters, and target-related biological processes and signaling pathways. Our research not only provides theoretical support for the molecular and pharmacological mechanisms of YGL capsule in HB treatment, but also provides new research methods for the study of the other traditional Chinese medicinal compounds.

100 Deals associated with Yinqu Capsule

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthenia	Phase 2	CN	Yangtze River Pharmaceutical Gp Nanjing Hailing Pharm Co. Ltd.	19 May 2010
Asthenia	Phase 2	CN	Nanjing Hailing Traditional Chinese Medicine Pharmaceutical Art Technical Research Co Lt	19 May 2010
Dyslipidemias	Phase 1	CN	Yangtze River Pharmaceutical Gp Nanjing Hailing Pharm Co. Ltd.	19 May 2010
Dyslipidemias	Phase 1	CN	Nanjing Hailing Traditional Chinese Medicine Pharmaceutical Art Technical Research Co Lt	19 May 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Yinqu Capsule

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation